{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:50:07Z","timestamp":1764510607115},"reference-count":17,"publisher":"Informa UK Limited","issue":"14","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,6,30]]},"DOI":"10.2217\/fon-2018-0116","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T10:45:42Z","timestamp":1525862742000},"page":"1335-1338","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Recent Breakthroughs in Metastatic Uveal Melanoma: A Cause for Optimism?"],"prefix":"10.1080","volume":"14","author":[{"given":"Joseph J","family":"Sacco","sequence":"first","affiliation":[{"name":"Liverpool Ocular Oncology Research Group, Department of Molecular & Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK"},{"name":"Department of Medical Oncology, Clatterbridge Cancer Centre, Bebington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Kalirai","sequence":"additional","affiliation":[{"name":"Liverpool Ocular Oncology Research Group, Department of Molecular & Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Kenyani","sequence":"additional","affiliation":[{"name":"Liverpool Ocular Oncology Research Group, Department of Molecular & Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos R","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Liverpool Ocular Oncology Research Group, Department of Molecular & Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy M","family":"Coulson","sequence":"additional","affiliation":[{"name":"Liverpool Ocular Oncology Research Group, Department of Molecular & Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK"},{"name":"Department of Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E","family":"Coupland","sequence":"additional","affiliation":[{"name":"Liverpool Ocular Oncology Research Group, Department of Molecular & Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK"},{"name":"Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.08.009"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.038"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.9554"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.07.003"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.06.005"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0066"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1321187"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30251-6"},{"key":"e_1_3_2_11_1","first-page":"P208","article-title":"Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials","volume":"5","author":"Carvajal R","year":"2017","unstructured":"Carvajal R , SatoT, ShoushtariAet al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials. J. Immunother. Cancer5, P208 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3086"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6096"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.8"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C000684200"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283364a08"},{"key":"e_1_3_2_17_1","volume-title":"14th International Congress of the Society for Melanoma Research","author":"Patel S","year":"2017","unstructured":"Patel S , LewisK, OlenckiTet al. A Phase II study of glembatumumab vedotin for metastatic uveal melanoma. Presented at: 14th International Congress of the Society for Melanoma Research. Brisbane, Australia, 18\u201321 October 2017."},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4968-3"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24956"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:49Z","timestamp":1719125089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":17,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,6,30]]}},"alternative-id":["10.2217\/fon-2018-0116"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0116","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}